Product Description
FACL6 Antibody | 61-419 | ProSci
Host: Rabbit
Reactivity: Human, Mouse
Homology: N/A
Immunogen: This FACL6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 240-270 amino acids from the Central region of human FACL6.
Research Area: Obesity, Signal Transduction
Tested Application: WB, IHC-P
Application: For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 78 kDa
Validation: N/A
Isoform: N/A
Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Clonality: Polyclonal
Clone: N/A
Isotype: Rabbit Ig
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: batch dependent
Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Alternate Name: Long-chain-fatty-acid--CoA ligase 6, Long-chain acyl-CoA synthetase 6, LACS 6, ACSL6, ACS2, FACL6, KIAA0837, LACS5
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: FACL6 is involved in activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. It plays an important role in fatty acid metabolism in brain and the acyl-CoAs produced may be utilized exclusively for the synthesis of the brain lipid. FACL6 is expressed predominantly in erythrocyte precursors, in particular in reticulocytes, fetal blood cells derieved from fetal liver, haemopoietic stem cells from cord blood, bone marrow, and brain. Expression is low at earlier stages of erythroid development but is very high in reticulocytes. This protein is involved in myelodysplastic syndrome (MDS) with basophilia, acute myelogenous leukemia (AML) with eosinophilia, and acute eosinophilic leukemia (AEL) . It is characterized by a chromosomal translocation t (5;12) (q31;p13) that involves ETV6 and ACSL6.